Hematopoietic stem cell transplantation (HSCT) is a rigorous therapy that carries significant risk of morbidity and mortality to individuals with hematologic malignancies undergoing this treatment. While relationships between psychosocial factors, immune function, and clinical outcomes have been documented in other cancer populations, similar studies of cancer patients undergoing HSCT have not yet been conducted. The clinical significance of these relationships may be particularly salient in this population given the critical role of a timely immune recovery and optimal immune regulation in preventing infections, mitigating risk for graft-versus-host disease, and eliminating malignant cells, thereby reducing morbidity and mortality. Evidence for the potential role of biobehavioral processes following HSCT is reviewed, mechanisms by which psychosocial factors may influence immune processes relevant to post-transplant outcomes are discussed, and a framework to ground future psychoneuroimmunology (PNI) research in this area is provided. The review suggests that the recovery period following HSCT may provide a ''window of opportunity'' during which interventions targeting stress-related behavioral factors can influence the survival, health, and well-being of HSCT recipients.
Introduction
Hematopoietic stem cell transplantation (HSCT) is a rigorous therapy that carries significant risk of morbidity and mortality to individuals with hematologic malignancies undergoing this treatment. While there are a growing number of psychoneuroimmunology (PNI) studies of other cancer populations, there is a dearth of research on patients undergoing HSCT. The clinical significance of PNI relationships may be particularly salient in this population given the critical role of a timely immune recovery and optimal immune regulation in reducing morbidity and complications and preventing recurrence. This review focuses on evidence suggesting the importance of biobehavioral processes in the recovery following HSCT and potential mechanisms by which psychosocial factors influence immune processes relevant to critical post-transplant outcomes. Fig. 1 outlines the biobehavioral pathways discussed.
Hematopoietic stem cell transplantation (HSCT)
HSCT is performed by administering intense chemotherapy with or without radiation therapy followed by infusion of autologous or allogeneic hematopoietic stem cells. See Copelan (2006) for an excellent overview. In brief, autologous transplantation involves the infusion of the patients' own hematopoietic stem cells and allows patients to receive high-dose chemotherapy that can eradicate disease at the cost of ablating the bone marrow. It is most frequently used for multiple myeloma, other plasma cell disorders, and aggressive lymphomas. In allogeneic transplantation, patients receive hematopoietic stem cells or bone marrow product from an HLA-matched donor or umbilical cord. It is used to treat acute and chronic leukemias, myelodysplastic and myeloproliferative disorders, lymphomas, and aplastic anemias and other bone marrow failure disorders. While high-dose therapy provides short-term disease control, the therapeutic potential of allogeneic transplant derives from a ''graft-versus-malignancy'' effect in which donorderived immune cells detect and eliminate remaining circulating malignant cells. Consequently, reduced intensity, nonmyeloablative regimens have increasingly been used to take advantage of this effect while reducing the toxicity and morbidity.
HSCT is a risky procedure with a high rate of treatment-related morbidity and mortality. Common side effects include nausea, diarrhea, anorexia, and fatigue. Significant early complications include gastrointestinal mucosal injury (mucositis), veno-occlusive disease of the liver, pulmonary failure, and infections. Allogeneic transplantation also carries a high risk of acute graft-versus-host disease (aGVHD). Two-year allogeneic transplant-related mortality
